5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphoma

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphomaПодробнее

What’s new in the initial management of Hodgkin lymphoma?Подробнее

Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHLПодробнее

Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trialПодробнее

The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin LymphomaПодробнее

Long-Term Efficacy and Safety of Brentuximab Vedotin in Hodgkin Lymphoma PatientsПодробнее

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HLПодробнее

Seven-year OS analysis from ECHELON-1: brentuximab vedotin + AVD versus ABVD in Hodgkin lymphomaПодробнее

Five year update of ECHELON-1 for classical Hodgkin lymphomaПодробнее

ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVDПодробнее

A 10-year PFS simulation model based on the ECHELON-1 trial in Hodgkin lymphomaПодробнее

Real-world data on brentuximab vedotin with chemotherapy in Hodgkin lymphomaПодробнее

Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHLПодробнее

ECHELON-1 Trial Shows Continued Efficacy Over Time in Hodgkin LymphomaПодробнее

Updated 3-Year Findings of ECHELON-1 Trial Presented for Classical Hodgkin LymphomaПодробнее

Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 studyПодробнее

Results of ECHELON-1 study for Hodgkin LymphomaПодробнее

Updates from the ECHELON-1 studyПодробнее

Echelon-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 cla...Подробнее

Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?Подробнее